Lyra Therapeutics, Inc. (LYRA): debt financing — Lyra Therapeutics receives default notice for $484K unpaid rent; wind-down continues

Lyra Therapeutics, Inc.

Received default notice from sublessor RVAC on Feb 23, 2026 for unpaid rent at Waltham office.
Aggregate unpaid rent totals $484,431.92 as of the notice date.
Company previously announced ceasing operations and wind-down on Jan 12, 2026.
Proposed sublease termination with Jan 31, 2026 surrender, but parties could not agree.
No assurance that obligations can be resolved outside of a bankruptcy process.

item 2.04

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Lyra Therapeutics, Inc. reported a default on lease obligation with RVAC Medicines (US), Inc..

Instrument: lease obligation
Counterparty: RVAC Medicines (US), Inc.
Event: default

Exact text from the filing

On February 23, 2026, Lyra Therapeutics, Inc. (the “Company”) received a notice of default from RVAC Medicines (US), Inc. (“RVAC”) under the sublease agreement dated December 21, 2023 (the “Sublease”) between RVAC, as sublessor, and the Company, as sublessee, for office space located at 880 Winter Street, Suite 1002, Waltham, MA 02451 (the “Premises”).

View on SEC.gov

41 debt financings filed in the last 30 days. Browse all debt financings →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-083251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.